Online business for sale · M&A analysis

Patented Pediatric Supplement Brand for Sale

This is a scaled pediatric health brand with a defensible formulation, established professional-distribution relationships and a meaningful subscription base. The central thesis is that a buyer can compound an already profitable platform by improving retention and owned-channel conversion while reducing dependence on a dominant marketplace. The opportunity is unusually specific: the brand has a large email audience, no subscriber-only pricing, no established SMS program and early physician-influencer traction. The principal questions are whether the published earnings normalize cleanly, whether clinical and patent protections remain durable, and whether customer economics support the advertised valuation after inventory and working-capital needs are included.

Pediatric supplements ecommerce and wholesale brandUnited States / national distribution

View all BrokerAccord listings ↗

Asking price$22M–$24M, plus inventoryApproximate public range

Revenue$13.5M–$15M annual revenueApproximate public range

Earnings$3.75M–$4.25M claimed SDEApproximate public range

TrafficNot publicly disclosedApproximate public range

CustomersApproximately 25,000–35,000 active subscribersApproximate public range

Operating historyMore than 15 yearsApproximate public range

Indicative valuationAbout 5.8x claimed SDECalculated from public materials

Recurring revenueApproximately 25%–30%Public materials

Marketplace concentrationApproximately 85%–90% of revenuePublic materials

Active subscribersApproximately 25,000–35,000Public materials

Email audienceApproximately 45,000–55,000 profilesPublic materials

Distribution footprintTens of thousands of pharmacy and hospital locationsPublic materials

Investment thesis

The asset combines recurring consumer demand, professional-channel credibility and intellectual-property protection. The thesis holds if the claimed SDE is durable, the patent and clinical positioning remain commercially useful, and a buyer can grow direct-to-consumer revenue without weakening marketplace performance or increasing customer-acquisition costs disproportionately.

Business model and revenue quality

Revenue comes from supplements sold through a dominant online marketplace, the brand's direct channel and pharmaceutical-wholesaler distribution. Roughly one quarter to one third of revenue is described as recurring through active subscriptions. That recurring component is valuable, but the marketplace still accounts for the large majority of sales, so subscription cohort data and channel-level contribution margins matter more than the headline recurring-revenue percentage.

Economics and valuation

The public asking price implies approximately 5.8 times claimed SDE before the unspecified inventory payment. That is a premium small-business multiple and requires confidence in normalization, customer retention, regulatory continuity and the transferability of supplier and distributor relationships. Inventory and working capital could materially increase the buyer's total cash requirement.

Defensibility

The published case rests on a granted US patent, a randomized controlled trial in a peer-reviewed medical journal and distribution through large pharmaceutical wholesalers. These are stronger barriers than branding alone, but their value depends on remaining patent life, claim scope, enforceability, regulatory compliance and whether the study supports the precise marketing claims being made.

Customer and channel quality

The active subscription base and strong email engagement create an owned relationship with customers, while pharmacy and hospital availability supports trust. However, concentration in one marketplace exposes the business to ranking, advertising, account and policy risk. The higher-margin direct channel is growing, which could improve both customer ownership and margin if acquisition economics remain attractive.

Operations and transferability

A small tenured team reportedly manages marketplace, website, operations and brand functions. The seller is retiring and has offered structured transition support, including introductions to physician and wholesaler relationships. Buyers should test which relationships are institutional and which still depend on the founder.

Growth path

The most credible near-term levers are subscription optimization, lifecycle messaging and systematic physician-influencer acquisition. International expansion and three scoped product lines could add scale, but they require more capital, regulatory work and forecasting discipline. The strongest plan would sequence low-capital retention improvements before geographic or product-line expansion.

What must be verified

A buyer should reconcile revenue and SDE to source records, separate marketplace from direct and wholesale contribution, validate subscriber retention by cohort, review patent and clinical documentation, and quantify inventory, chargeback, return and working-capital requirements.

Opportunity map

Introduce subscriber-specific pricing and retention journeys, then test the impact on churn, order frequency and contribution margin.
Build SMS and segmented email programs around the existing owned audience rather than relying solely on marketplace demand.
Scale the early physician-influencer program with trackable referral economics and compliant health-claim controls.
Expand direct-to-consumer mix to improve customer ownership and margin while preserving marketplace rank and velocity.
Stage international and new-product launches only after validating regulatory requirements, inventory turns and channel economics.

Risk map

A single marketplace represents the large majority of reported revenue.
The asking price is stated before inventory, increasing total transaction and working-capital needs.
Patent, clinical-study and regulatory value may be narrower or shorter-lived than the marketing summary suggests.
Subscription count does not by itself establish retention quality, lifetime value or profitability.
Key physician, wholesaler or supplier relationships may depend on the retiring founder.

Questions before conviction

What a buyer should establish next.

What are monthly subscriber additions, cancellations, reactivations and cohort retention for the last 36 months?
How do gross margin, contribution margin and return rates differ across marketplace, direct and wholesale channels?
What add-backs bridge reported operating profit to the claimed SDE?
What inventory amount is excluded from the asking price, and what are SKU-level turns, expiry exposure and write-offs?
What is the remaining patent term, claim scope and history of challenges or enforcement?
Which marketing claims are directly supported by the published clinical study and approved legal review?
What percentage of wholesale sell-in becomes verified sell-through, returns or chargebacks?
Which supplier, physician and wholesaler agreements require consent or renegotiation on a change of control?
What duties still require the seller, and which team members have signed transferable employment, confidentiality and IP agreements?

Analysis by Adriaan Brits

Commercial judgment informed by operating experience.

Founder and CEO of BrokerAccord.com. More than 20 years of firsthand online-business ownership, with experience across analytics, marketing, digital operations and transaction readiness.

View LinkedIn profile ↗

Complete source record

See the broker and exact source figures.

Verify your email to open the original source, broker details and exact figures behind this analysis. A standard BrokerAccord buyer profile will be created if you do not already have one.